<div class='row'>
    <div class='col-md-10 col-md-offset-1'>
        <article>
            <header><h1>Generic residue numbering</h1></header>
            <div style='width:650px;float:right;'>
                <figure>
                  <img src="/static/home/images/documentation/TM2_bulge.jpg">
                  <img src="/static/home/images/documentation/TM4_constriction.jpg">
                    <figcaption>
                        <strong>Figure 1</strong>. A bulge in helix 2 of the Beta-2 adrenergic receptor (left) and a
                        constriction in helix 4 of the Histamine H1 receptor (right) create offsets in the
                        sequence-based generic numbers when compared to receptors that lack the bulge/constriction.
                    </figcaption>
                </figure>
            </div>

             <p>Sequence-based generic GPCR residue numbering schemes<sup>1</sup> exist for class A
            (Ballesteros-Weinstein, BW<sup>2</sup>) B (Wootten<sup>3</sup>), C (Pin<sup>4</sup>), and F
            (Wang<sup>5</sup>). In these systems, the first number denotes the helix (1-7) and the second the residue
            position relative to the most conserved position, which is assigned the number 50. For example, 6.51 denotes
            a residue in transmembrane helix 6, one position after the most conserved residue (6.50). The reference
            helix conserved positions differ between the GPCR classes.</p>

            <p>Recent GPCR crystal structures have revealed frequent helix bulges and constrictions in several
            transmembrane helices<sup>6</sup>. Structural superimposition makes it clear that these cause a gap that offsets all
            the following residue numbers when compared to an undistorted helix, i.e. the structurally equivalent
            residues no longer have the same number (Fig. 1).</p>

            <p>The GPCRDB numbering scheme<sup>1</sup> is the first that is based on crystal structures and corrects for
            helix bulges and constrictions. GPCRDB numbers are distinguished by a unique separator x and may be used
            alone, e.g. 5x47, or together with one of the sequence-based schemes, e.g. 5.46x47. A bulge residue is
            assigned the same number as the preceding residue followed by a 1, e.g. 551 for a bulge following
            position 55.</p>

            <p>
            GPCRDB offers a suite of tools making it easier to use generic residue numbers:
                <ul>
                    <li>Structure-based <a href='/alignment/targetselection'>sequence alignments</a>
                        gapped to account for bulges and constrictions</li>
                    <li><a href='/residue/residuetable'>Lookup tables</a> with
                        receptor-specific and generic residue numbers</li>
                    <li><a href='/structure/generic_numbering_index'>3D Structure numbering</a> along with visualization tools for PyMol and Maestro</li>
                    <li><a href='http://www.gpcr.org/7tm/?wicket:bookmarkablePage=:nl.ru.cmbi.mcsis.web.pages.info.UtopiaDocumentGPCRDBPage'>
                        Pdf reader</a> with automatic residue annotation</li>
                </ul>
            </p>

            <p>GPCRDB cross-class alignments contain each of the numbering schemes, which may be distinguished in text
            by appending the letter of the class, e.g. 2x52ax59b. The Lookup tables tool also provides the alternative
            class A numbering schemes by Oliveira<sup>7</sup> and Baldwin/Schwartz<sup>8,9</sup>.</p>

            <p><h4>References</h4></p>

            <p>
            <a href="http://dx.doi.org/10.1016/j.tips.2014.11.001">[1]</a> V Isberg, C de Graaf, A Bortolato,
            V Cherezov, V Katritch, F Marshall, S Mordalski, J-P Pin, RC Stevens, G Vriend, DE Gloriam, "Generic GPCR
            Residue Numbers - Aligning Topology Maps While Minding The Gaps", <strong>2015</strong>,
            <em>Trends Pharmacol Sci</em>, 36(1), 22–31.<br>
            <a href="http://dx.doi.org/10.1016/S1043-9471(05)80049-7">[2]</a> JA Ballesteros and H Weinstein,
            “Integrated methods for the construction of three-dimensional models and computational
            probing of structure-function relations in G protein-coupled receptors”, <strong>1995</strong>, <em>Methods
            Neurosci</em>, 25, 366–428.<br>
            <a href="http://dx.doi.org/10.1073/pnas.1221585110">[3]</a> D Wootten, J Simms, LJ Miller, A Christopoulos,
            PM Sexton, "Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased
            family B G protein-coupled receptor conformations", <strong>2013</strong>, <em>Proc Natl Acad Sci</em>,
            110(13), 5211-5216.<br>
            <a href="http://dx.doi.org/10.1016/S0163-7258(03)00038-X">[4]</a> J-P Pin, T Galvez, L Prezeau, "Evolution,
            structure, and activation mechanism of family 3/C G-protein-coupled receptors", <strong>2003</strong>,
            <em>Pharmacol Ther</em>, 98(3), 325-354.<br>
            <a href="http://dx.doi.org/10.1038/ncomms5355">[5]</a> C Wang, H Wu, T Evron, E Vardy, G Han, X-P Huang, SJ Hufeisen,
            TJ Mangano,  DJ Urban, V Katritch, V Cherezov, MG Caron, BL Roth, RC Stevens, "Structural basis for
            Smoothened receptor modulation and chemoresistance", <strong>2014</strong>, <em>Nat Commun</em>, 5, 4355.<br>
            <a href="http://dx.doi.org/10.3390/ijms15057841">[6]</a> R van der Kant, G Vriend, "Alpha-Bulges in G Protein-Coupled
            Receptors", <strong>2014</strong>, <em>Int J Mol Sci</em>, 15(5), 7841-7864.<br>
            <a href="http://dx.doi.org/10.1007/BF00125323">[7]</a> L Oliveira, ACM Paiva,
            G Vriend, "A common motif in G-protein-coupled seven transmembrane helix receptors", <strong>1993</strong>,
            <em>J Comput Aided Mol Des</em>, 7(6), 649–658.<br>
            <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC413383/">[8]</a> JM Baldwin,
            “The probable arrangement of the helices in G protein-coupled receptors”, <strong>1993</strong>, <em>
            EMBO J</em>, 12(4), 1693–703<br>
            <a href="http://dx.doi.org/10.1016/0958-1669(94)90054-X">[9]</a> TW Schwartz, “Locating ligand-binding sites
            in 7TM receptors by protein engineering”, <strong>1994</strong>, <em>Curr Opin Biotechnol</em>, 5(4), 434–44.
            </p>
        </article>
    </div>
</div>